LeMaitre Vascular Sees Q1 EPS $0.36-$0.41 vs $0.34 Est., Sales $50.5M-$52.9M vs $50.21M Est.; Sees FY24 EPS $1.60-$1.71 vs $1.53 Est., Sales $209.7M-$214.3M vs $209.99M Est.
Portfolio Pulse from Benzinga Newsdesk
LeMaitre Vascular forecasts Q1 EPS of $0.36-$0.41, surpassing the $0.34 estimate, with sales expected between $50.5M-$52.9M, also above the $50.21M estimate. For FY24, the company anticipates an EPS of $1.60-$1.71, exceeding the $1.53 estimate, and sales projections of $209.7M-$214.3M, slightly above the $209.99M estimate.
February 27, 2024 | 10:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LeMaitre Vascular projects higher than expected Q1 and FY24 earnings and sales, indicating strong financial health and potential growth.
LeMaitre Vascular's projection of higher than expected earnings and sales for both Q1 and FY24 suggests a positive outlook on the company's financial health and growth potential. This is likely to instill confidence in investors, potentially leading to an increase in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100